Geniposide and Harpagoside Functionalized Cerium Oxide Nanoparticles as a Potential Neuroprotective

Int J Mol Sci. 2024 Apr 11;25(8):4262. doi: 10.3390/ijms25084262.

Abstract

Alzheimer's disease is associated with protein aggregation, oxidative stress, and the role of acetylcholinesterase in the pathology of the disease. Previous investigations have demonstrated that geniposide and harpagoside protect the brain neurons, and cerium nanoparticles (CeO2 NPs) have potent redox and antioxidant properties. Thus, the effect of nanoparticles of Ce NPs and geniposide and harpagoside (GH/CeO2 NPs) on ameliorating AD pathogenesis was established on AlCl3-induced AD in mice and an aggregation proteins test in vitro. Findings of spectroscopy analysis have revealed that GH/CeO2 NPs are highly stable, nano-size, spherical in shape, amorphous nature, and a total encapsulation of GH in cerium. Treatments with CeO2 NPs, GH/CeO2 NPs, and donepezil used as positive control inhibit fibril formation and protein aggregation, protect structural modifications in the BSA-ribose system, have the ability to counteract Tau protein aggregation and amyloid-β1-42 aggregation under fibrillation condition, and are able to inhibit AChE and BuChE. While the GH/CeO2 NPs, treatment in AD induced by AlCl3 inhibited amyloid-β1-42, substantially enhanced the memory, the cognition coordination of movement in part AD pathogenesis may be alleviated through reducing amyloidogenic pathway and AChE and BuChE activities. The findings of this work provide important comprehension of the chemoprotective activities of iridoids combined with nanoparticles. This could be useful in the development of new therapeutic methods for the treatment of neurodegenerative diseases.

Keywords: Alzheimer’s disease; acetylcholinesterase; amyloid-β1–42; butyrylcholinesterase; cognitive performance; nanoparticles; tau protein.

MeSH terms

  • Acetylcholinesterase* / metabolism
  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / metabolism
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Cerium* / chemistry
  • Cerium* / pharmacology
  • Disease Models, Animal
  • Iridoids* / chemistry
  • Iridoids* / pharmacology
  • Male
  • Metal Nanoparticles / chemistry
  • Mice
  • Nanoparticles / chemistry
  • Neuroprotective Agents* / chemistry
  • Neuroprotective Agents* / pharmacology

Substances

  • Cerium
  • Iridoids
  • ceric oxide
  • Neuroprotective Agents
  • geniposide
  • Acetylcholinesterase
  • Amyloid beta-Peptides

Grants and funding

This research was supported by the Instituto Politecnico Nacional grant number 20230610.